多发性骨髓瘤患者血清HSP90 mRNA、β2-MG的表达水平及其与患者预后的关系

Expression level of serum HSP90 mRNA and β2-MG in patients with multiple myeloma and its relationship with prognosis

目的:探讨多发性骨髓瘤患者血清热休克蛋白90(HSP90)mRNA、β2-微球蛋白(β2-MG)的表达水平及其与患者预后的关系。方法:选取我院94例多发性骨髓瘤患者作为骨髓瘤组,并分为ISS I期26例、ISS II期36例、ISS III期32例;同期选取96例健康体检者作为健康对照组。实时荧光定量PCR(qRT-PCR)法检测血清HSP90 mRNA表达水平,酶联免疫吸附(ELISA)法检测血清β2-MG表达水平。Pearson法分析多发性骨髓瘤患者血清HSP90 mRNA与β2-MG水平的相关性。Kaplan-Meier法分析多发性骨髓瘤患者预后与血清HSP90 mRNA、β2-MG表达水平的关系。多发性骨髓瘤患者预后的影响因素采用Cox回归分析。结果:骨髓瘤组血清HSP90 mRNA、β2-MG水平均明显高于健康对照组(P<0.001)。多发性骨髓瘤ISS III期患者血清HSP90 mRNA、β2-MG水平均明显高于ISS II期和ISS I期患者,ISS II期患者血清HSP90 mRNA、β2-MG水平均明显高于ISS I期患者(P<0.001)。多发性骨髓瘤患者血清HSP90 mRNA与β2-MG水平呈正相关(r=0.630,P<0.001)。HSP90 mRNA高表达多发性骨髓瘤患者3年生存率(35.42%)明显低于HSP90 mRNA低表达患者(63.04%)(P<0.01);β2-MG高表达多发性骨髓瘤患者3年生存率(35.56%)明显低于β2-MG低表达患者(61.22%)(P<0.05)。血清HSP90 mRNA、β2-MG是影响多发性骨髓瘤患者预后的独立危险因素(P<0.05)。结论:HSP90 mRNA、β2-MG在多发性骨髓瘤患者血清中呈高表达,检测二者水平对多发性骨髓瘤患者病情评价及预后评估有潜在参考价值。

Objective:To investigate the relationship between the expression levels of heat shock protein 90(HSP90)mRNA andβ2-microglobulin(β2-MG)and prognosis in patients with multiple myeloma.Methods:A total of 94 patients with multiple myeloma admitted to our hospital were selected as myeloma group,and divided into ISS stage I(26 cases),ISS II stage(36 cases)and ISS III stage(32 cases).At the same time,96 healthy people were selected as the healthy control group.Real-time quantitative PCR(qRT-PCR)was used to detect the expression level of HSP90 mRNA in serum.Enzyme linked immunosorbent assay(ELISA)was used to detect the expression level of serumβ2-MG.Pearson method was used to analyze the correlation between serum HSP90 mRNA level andβ2-MG level in patients with multiple myeloma.Kaplan-Meier method was used to analyze the relationship between the prognosis of patients with multiple myeloma and the expression levels of serum HSP90 mRNA andβ2-MG.The prognostic factors of multiple myeloma patients was analyzed by Cox regression analysis.Results:The levels of serum HSP90 mRNA andβ2-MG in myeloma group were significantly higher than those in healthy control group(P<0.001).The levels of serum HSP90 mRNA andβ2-MG in patients with multiple myeloma in ISS stage III were higher than those in patients in ISS stage II and ISS stage I.The levels of serum HSP90 mRNA andβ2-MG in patients with ISS stage II were higher than those in patients with ISS stage I(P<0.001).There was a positive correlation between serum HSP90 mRNA level andβ2-MG level in patients with multiple myeloma(r=0.630,P<0.001).The 3-year survival rate(35.42%)of multiple myeloma patients with high expression of HSP90 mRNA was lower than that(63.04%)of patients with low expression of HSP90 mRNA(P<0.01).The 3-year survival rate(35.56%)of multiple myeloma patients with high expression ofβ2-MG was lower than that(61.22%)of patients with low expression ofβ2-MG(P<0.05).Serum HSP90 mRNA andβ2-MG were independent risk factors of prognosis in patients with multiple myeloma(P<0.05).Conclusion:HSP90 mRNA andβ2-MG are highly expressed in the serum of patients with multiple myeloma.The detection of the levels of HSP90 mRNA andβ2-MG has potential reference value for evaluating the condition and prognosis of patients with multiple myeloma.